Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection.

Shan L, Deng K, Gao H, Xing S, Capoferri AA, Durand CM, Rabi SA, Laird GM, Kim M, Hosmane NN, Yang HC, Zhang H, Margolick JB, Li L, Cai W, Ke R, Flavell RA, Siliciano JD, Siliciano RF.

Immunity. 2017 Oct 17;47(4):766-775.e3. doi: 10.1016/j.immuni.2017.09.014.

2.

A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides.

Laird GM, Eisele EE, Rabi SA, Nikolaeva D, Siliciano RF.

J Antimicrob Chemother. 2014 Apr;69(4):988-94. doi: 10.1093/jac/dkt471. Epub 2013 Nov 24.

3.

Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins.

Dobrowsky TM, Rabi SA, Nedellec R, Daniels BR, Mullins JI, Mosier DE, Siliciano RF, Wirtz D.

Sci Rep. 2013 Oct 22;3:3014. doi: 10.1038/srep03014.

4.

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, Chioma S, Moore RD, Siliciano RF.

J Clin Invest. 2013 Sep;123(9):3848-60. doi: 10.1172/JCI67399. Epub 2013 Aug 27.

5.

Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.

Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, Siliciano JD, Siliciano RF.

PLoS Pathog. 2013;9(5):e1003398. doi: 10.1371/journal.ppat.1003398. Epub 2013 May 30.

6.

A novel PCR assay for quantification of HIV-1 RNA.

Shan L, Rabi SA, Laird GM, Eisele EE, Zhang H, Margolick JB, Siliciano RF.

J Virol. 2013 Jun;87(11):6521-5. doi: 10.1128/JVI.00006-13. Epub 2013 Mar 27.

7.

Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.

Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA.

Nat Med. 2012 Sep;18(9):1378-85.

8.

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF.

Immunity. 2012 Mar 23;36(3):491-501. doi: 10.1016/j.immuni.2012.01.014. Epub 2012 Mar 8.

9.

A quantitative basis for antiretroviral therapy for HIV-1 infection.

Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, Shen L, Siliciano RF.

Nat Med. 2012 Feb 19;18(3):446-51. doi: 10.1038/nm.2649.

10.

HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy.

Durand CM, Ghiaur G, Siliciano JD, Rabi SA, Eisele EE, Salgado M, Shan L, Lai JF, Zhang H, Margolick J, Jones RJ, Gallant JE, Ambinder RF, Siliciano RF.

J Infect Dis. 2012 Mar 15;205(6):1014-8. doi: 10.1093/infdis/jir884. Epub 2012 Jan 24.

11.

Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

Salgado M, Rabi SA, O'Connell KA, Buckheit RW 3rd, Bailey JR, Chaudhry AA, Breaud AR, Marzinke MA, Clarke W, Margolick JB, Siliciano RF, Blankson JN.

Retrovirology. 2011 Dec 5;8:97. doi: 10.1186/1742-4690-8-97.

12.

CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors.

O'Connell KA, Rabi SA, Siliciano RF, Blankson JN.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E689-98. doi: 10.1073/pnas.1108866108. Epub 2011 Aug 22.

13.

Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.

Spivak AM, Salgado M, Rabi SA, O'Connell KA, Blankson JN.

J Virol. 2011 Oct;85(19):10399-403. doi: 10.1128/JVI.05409-11. Epub 2011 Jul 27.

14.

A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs.

Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, Siliciano RF.

Sci Transl Med. 2011 Jul 13;3(91):91ra63. doi: 10.1126/scitranslmed.3002304.

15.

Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model.

Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Irizarry RA, Zhang H, Margolick JB, Siliciano JD, Siliciano RF.

J Virol. 2011 Jun;85(11):5384-93. doi: 10.1128/JVI.02536-10. Epub 2011 Mar 23.

16.

Short communication: dynamic constraints on the second phase compartment of HIV-infected cells.

Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):759-61. doi: 10.1089/AID.2010.0199. Epub 2011 Jan 15.

17.

Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection.

Rabi SA, O'Connell KA, Nikolaeva D, Bailey JR, Jilek BL, Shen L, Page KR, Siliciano RF, Blankson JN.

J Virol. 2011 Jan;85(2):979-86. doi: 10.1128/JVI.01721-10. Epub 2010 Nov 10.

18.

Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA.

Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, Adams RJ, Bartizal C, Varrone J, Rabi SA, Graham DR, Tarwater PM, Mankowski JL, Clements JE.

J Infect Dis. 2010 Jul 1;202(1):161-70. doi: 10.1086/653213.

19.

A novel method for determining the inhibitory potential of anti-HIV drugs.

Shen L, Rabi SA, Siliciano RF.

Trends Pharmacol Sci. 2009 Dec;30(12):610-6. doi: 10.1016/j.tips.2009.09.003. Review.

20.

A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.

Dinoso JB, Rabi SA, Blankson JN, Gama L, Mankowski JL, Siliciano RF, Zink MC, Clements JE.

J Virol. 2009 Sep;83(18):9247-57. doi: 10.1128/JVI.00840-09. Epub 2009 Jul 1.

21.

The eradication of a large scabies outbreak using community-wide health education.

Kanaaneh HA, Rabi SA, Badarneh SM.

Am J Public Health. 1976 Jun;66(6):564-7.

Supplemental Content

Support Center